Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.

Also called NCT05309460

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 600 participants (planned count) (from the registry)
Sponsor
Nebraska Methodist Health System (from the registry)
Registry
  • NCT NCT05309460
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05309460. Randomized; no masking; primary purpose treatment. Start 2022-06-20 (actual); primary completion 2024-05-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial
Condition
Postpartum Preeclampsia
Condition
Hypertension in Pregnancy
Intervention (Drug)
Labetalol Oral Tablet
Intervention (Drug)
NIFEdipine ER
Lead sponsor
Nebraska Methodist Health System (class: other)

Record details

Record id
cardio:ct-nct05309460
Content hash
74c1a80eecfeef08d69064c5b73f0ef64fef210587a3e4e044a47a9f448074f8